Genexine Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	2.3yrs
Board average tenure	2.3yrs

Recent management updates

Recent updates

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

Mar 14

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 19

CEO

Genexine has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jungwon Woo	President & Director	2.3yrs	no data	no data
Neil K. Warma	President & Director	2yrs	no data	no data
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	no data	no data	5.88% ₩ 18.7b
Sung-June Hong	Executive VP	no data	no data	no data
Jongsoo Lee	Senior Manager of IR & PR	no data	no data	no data
Hyun Jin Park	EVP of Corporate Development	2.3yrs	no data	no data
Jong Sup Park	Chief Medical Officer	5.2yrs	no data	no data
Jang Hee Lee	EVP of Operations	2.3yrs	no data	no data
Ki Yong Kim	SVP of Bio Research Institute	2.3yrs	no data	no data
Chul Jun Hyun	Auditor & Director	2.3yrs	no data	no data

2.3yrs

Average Tenure

Experienced Management: A095700's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jungwon Woo	President & Director	2.3yrs	no data	no data
Neil K. Warma	President & Director	2yrs	no data	no data
Young-Chul Sung	Founder & Chairman of the Scientific Advisory Board	2.3yrs	no data	5.88% ₩ 18.7b
Sung-June Hong	Executive VP	2.3yrs	no data	no data
Chul Jun Hyun	Auditor & Director	2.3yrs	no data	no data
Young-Jin Kim	Chairman of BOD	2.3yrs	no data	no data
Keon Pai Jin	Non-Executive Director	2.3yrs	no data	no data
Mijung Ahn	Member of Scientific Advisory Board	2.3yrs	no data	no data
Peter Laivins	Director	2.3yrs	no data	no data
Hyeok Jong Lee	Director	2.3yrs	no data	no data
Heeseop Shin	Member of Scientific Advisory Board	2.3yrs	no data	no data
Munseok Gang	Member of Scientific Advisory Board	2.3yrs	no data	no data

2.3yrs

Average Tenure

67yo

Average Age

Experienced Board: A095700's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Genexine Management

Management criteria checks 1/4

Key information

Recent management updates

No independent directors

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

Genexine, Inc., Annual General Meeting, Mar 29, 2021

Recent updates

Full year 2023 earnings released: ₩1,652 loss per share (vs ₩1,715 loss in FY 2022)

Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?

New minor risk - Revenue size

New minor risk - Share price stability

Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority (BPOM)

Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study

Ajinomoto Co., Inc. (TSE:2802) agreed to acquire remaining 25% stake in Ajinomoto Genexine Co., Ltd from Genexine, Inc. (KOSDAQ:A095700) for KRW 19.3 billion.

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for Its Promising DNA Vaccine for Advanced Cervical Cancer

Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine, Inc. has completed a Follow-on Equity Offering in the amount of KRW 82.044713 billion.

No independent directors

Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

No independent directors

First quarter 2021 earnings released: EPS ₩861 (vs ₩628 loss in 1Q 2020)

Genexine (KOSDAQ:095700) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Genexine, Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩94,300

Turret Capital Management Signs A Definitive License Agreement with Genexine, Inc

New 90-day low: ₩103,600

Genexine, Inc. and NeoimmuneTech, Inc. Releases Data for Their Phase 1B/2 Study of Gx-I7/Nt-I7 and Keytruda® in Patients with Triple-Negative Breast Cancer

New 90-day low: ₩104,000

New 90-day low: ₩109,500

Genexine, Inc. announced that it has received KRW 3.29761 billion in funding from Handok, Inc.

New 90-day high - ₩132,000

New 90-day high - ₩130,600

CEO

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age